

Can't find Dulera? Learn about the best alternative ICS/LABA inhalers for asthma, including Symbicort, Advair, Breo Ellipta, and AirDuo RespiClick.
If you rely on Dulera to manage your asthma and your pharmacy says it's out of stock, you need options — fast. Asthma doesn't wait for supply chains to sort themselves out, and going without a controller inhaler can lead to worsening symptoms or even a serious flare-up.
The good news is that Dulera is not the only ICS/LABA combination inhaler on the market. Several alternatives work in a very similar way and may be easier to find — and in some cases, less expensive. In this post, we'll explain what Dulera does, how it works, and walk through the best alternatives available in 2026.
Dulera (Mometasone Furoate/Formoterol Fumarate Dihydrate) is a combination metered-dose inhaler that contains two medications:
By combining an anti-inflammatory with a bronchodilator, Dulera addresses two key aspects of asthma: the underlying inflammation and the tightening of airways that causes wheezing, coughing, and shortness of breath.
Dulera is taken as 2 inhalations twice daily and is FDA-approved for patients 5 years and older. It's a maintenance medication — not a rescue inhaler. For a detailed explanation, see our post on how Dulera works.
Because Dulera has been affected by supply shortages and has no generic equivalent, many patients and doctors are exploring alternatives. Here are the top options.
Symbicort is probably the closest alternative to Dulera. Like Dulera, it combines an ICS with the same LABA — Formoterol. The ICS component is Budesonide instead of Mometasone, but both work to reduce airway inflammation.
Key facts about Symbicort:
Because Symbicort shares the same LABA (Formoterol) as Dulera, the transition for most patients is straightforward. Your doctor can help determine the right Budesonide dose to match your current Mometasone strength.
Advair has been one of the most widely prescribed ICS/LABA inhalers for decades. It combines Fluticasone Propionate (ICS) with Salmeterol (LABA) and is available in two forms:
Key facts about Advair:
Advair uses a different LABA (Salmeterol) than Dulera's Formoterol. Salmeterol has a slightly slower onset of action but lasts just as long. For most patients, this difference is not clinically significant for daily maintenance therapy.
Breo Ellipta is a newer ICS/LABA option with one major advantage: once-daily dosing. Instead of twice a day, you take just one inhalation each morning.
Key facts about Breo Ellipta:
If you find it hard to remember twice-daily dosing, Breo Ellipta's once-a-day schedule may be a better fit for your lifestyle.
AirDuo RespiClick is another ICS/LABA option. It contains the same active ingredients as Advair but comes in a breath-activated dry powder inhaler — meaning you don't need to coordinate pressing and breathing at the same time.
Key facts about AirDuo RespiClick:
Switching inhalers should always be done with your doctor's guidance. Here are some things to keep in mind:
Not being able to fill your Dulera prescription is stressful, but it doesn't mean you're out of options. Symbicort, Advair, Breo Ellipta, and AirDuo RespiClick are all proven ICS/LABA alternatives that your doctor can prescribe.
If you want to keep trying to find Dulera, use Medfinder to check pharmacy stock in your area — you might find it closer than you think. And for more tips, read our guide on how to find Dulera in stock near you.
To learn more about Dulera itself — including dosage, uses, and what to expect — check out What Is Dulera? and our guide to Dulera side effects.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.